Skip to content

Feasibility Study of an Intervention Therapeutic Education for Patients Treated With Androgen Deprivation

Feasibility Study of an Intervention Therapeutic Education for Patients Treated With Androgen Deprivation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02460549
Acronym
Nutriprophy
Enrollment
9
Registered
2015-06-02
Start date
2014-04-30
Completion date
2014-11-30
Last updated
2015-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

therapeutic patient education, insulinoresistance, empowerment, prostate cancer, oral endocrine therapy, side effects

Brief summary

The purpose of the study is to build and assess the feasibility of a therapeutic education program, constructed in collaboration with the urologists of the University Hospital of Saint Etienne. The aim of this therapeutic education program is to delay the onset or to reduce the amplitude of the development of insulin resistance and side effects of androgen deprivation therapy in patients treated with androgen deprivation in the context of an evolutive prostate cancer.

Interventions

Sponsors

Institut de Cancérologie de la Loire
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients supported in consultation Urology at the University Hospital North Saint Etienne. * Aged over 18 years * Having an evolutive prostate cancer * Patient treated with LHRH agonist for at least 6 months - Affiliated with the national health insurance system * And having completed the worksheet informed consent to participate in the program.

Exclusion criteria

* Refusal of participation, protected or under guardianship patients. * Patients unable to understand the study or unable to follow the educational sessions. * Patient (s) with documented cognitive or psychiatric history. * Geographical remotness (more than 100 Kms.)

Design outcomes

Primary

MeasureTime frame
Number of patients who refused to participate6 months

Secondary

MeasureTime frame
Number of patients in all sessions6 months
Number of withdrawals6 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026